This whitepaper discusses the role of non-immuno-oncology therapies for cancer in a world where immuno-oncology is playing a greater role.

This whitepaper dives into how representations and warranties insurance can play an integral part of negotiating transactions, winning bids, and finding a means of closing deals in today’s challenging M&A environment.

In this whitepaper, David Stastny summarizes the "seven deadly sins" that cause reduced purchase prices or failed M&A exits.

Whether seeking a partnership with another company to obtain funds, or looking to advance a drug candidate or technology, organizations need to present opportunities as attractively as possible to persuade potential partners.

In this whitepaper, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, what are the indications being pursued, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.

This whitepaper breaks down the six major stakeholder categories relevant to most life science companies, and shares key strategies for closing the knowledge gap between founders and their market success.

This white paper provides several topics to consider before investing in, planning and executing a business development initiative and the challenges presented by organizational structure and the importance of goal setting, flexibility and story-telling in a business context.

This whitepaper explains the security risks associated with the proliferation of SharePoint sites, the biggest challenges in developing extranets, and the most secure ways to share proprietary, highly confidential documents with third parties within a SharePoint environment.

This whitepaper is based on our web panel discussion on how to successfully move a life science organization from founding to exit.